Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product, Vykat XR, which led to a significant drop in the company's stock price [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized as overpriced and potentially unsafe for children according to a report by Scorpion Capital [2]. Group 2: Stock Performance - Following the publication of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Core Insights - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its officers or directors [1] Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, missing consensus estimates by $13.14 million, and reflecting a 30.1% year-over-year decline [2] - The company attributed delays in U.S. government contract awards to leadership transitions at agencies like NASA and budget shifts under the Trump administration [2] - Following the Q1 report, Redwire's stock price fell by $0.75 per share, or 6.63%, closing at $10.56 on May 12, 2025 [2] - For Q2 2025, Redwire revised its revenue outlook to $470 million to $530 million, indicating a 43.2% compound annual growth rate from 2023 to 2025 at midpoint, but reduced from previous guidance [2] - The company also withdrew its adjusted EBITDA forecast for 2025 due to volatility in government contracting and project cost challenges [2] - After the Q2 announcement, Redwire's stock price dropped by $4.23 per share, or 30.87%, closing at $9.47 on August 7, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Coty Inc. following disappointing financial results and guidance [1][3]. Financial Performance - On August 20, 2025, Coty reported an unexpected loss for its full fiscal year 2025 and fourth quarter, which led to a significant decline in stock price [3][4]. - The Chief Financial Officer attributed sluggish sales to various factors, including value-seeking behavior among consumers, innovation fatigue, and changes in anti-theft and immigration policies [3]. Stock Market Reaction - Following the announcement of the financial results, Coty's stock price dropped by $1.05 per share, representing a 21.6% decline, closing at $3.81 per share on August 21, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Axogen, Inc. and its officers or directors [1] Group 1: Company Developments - On August 25, 2025, Axogen announced that the FDA extended the PDUFA goal date for its Biologics License Application for Avance® Nerve Graft by three months to December 5, 2025 [3] - Following this announcement, Axogen's stock price decreased by $1.47 per share, or 9.04%, closing at $14.79 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Axogen for possible securities fraud or other unlawful business practices [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Agios Pharmaceuticals and its officers or directors, following a significant stock price drop due to a delayed FDA review of a key drug [1][3]. Group 1: Company Overview - Agios Pharmaceuticals, Inc. is under investigation for possible securities fraud related to its business practices [1]. - The company’s stock price fell by $4.48, or 11.03%, closing at $36.13 per share on September 4, 2025, after the announcement of a three-month extension for the FDA review of its drug PYRUKYND® [3]. Group 2: Regulatory Developments - The U.S. FDA extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® to December 7, 2025, impacting investor sentiment and stock performance [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Lineage, Inc. and its officers or directors [1] Group 1: Company Overview - Lineage, Inc. conducted its initial public offering on July 25, 2024, offering 56,882,051 shares at a price of $78.00 per share [3] - The company reported a total revenue of $1.29 billion for Q1 2025, reflecting a decrease of 2.7% compared to previous periods, attributed to more normal seasonal trends after elevated inventory levels [3] Group 2: Stock Performance - Following the Q1 2025 financial results announcement, Lineage's stock price dropped by $8.26 per share, or 14.62%, closing at $48.23 per share on April 30, 2025 [3]

Group 1 - A class action lawsuit has been filed against LifeMD, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors have until October 27, 2025, to request appointment as Lead Plaintiff if they purchased LifeMD securities during the Class Period [2] - Following the announcement of revised full-year 2025 guidance due to challenges in the Rex MD business, LifeMD's stock price dropped by $5.31, or 44.85%, closing at $6.53 per share [4] Group 2 - LifeMD's CFO stated that the company anticipates strong year-over-year growth in revenue and adjusted EBITDA despite temporary challenges [4] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [5]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of James Hardie Industries plc regarding potential securities fraud or unlawful business practices by the company and its officers [1] - James Hardie reported a 29% decline in first-quarter profit for the period ending June 30, 2025, and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [3] - Following the announcement of its financial results, James Hardie's ADR price fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [3] Company Overview - James Hardie Industries plc is facing scrutiny from investors and legal investigations related to possible securities fraud [1] - The company has experienced significant financial challenges, as indicated by the substantial decline in profit and negative earnings projections [3] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Skillz Inc. and its officers or directors [1] Group 1: Company Developments - On September 2, 2025, Skillz disclosed that Tether Studios and Tether Games plan to terminate all agreements with Skillz, effective September 1, 2025 [3] - Skillz has filed a lawsuit against Tether to block the termination of their agreements and is disputing Tether's reasons for ending the deal [3] - Following the announcement of the termination, Skillz's stock price fell by $1.50 per share, or 17.22%, closing at $7.21 per share on September 3, 2025 [4] Group 2: Legal Actions - Pomerantz LLP is advising investors of Skillz to contact them regarding the investigation into potential securities fraud [1] - The firm has a long history of handling corporate, securities, and antitrust class litigation, recovering multimillion-dollar damages for victims of securities fraud [5]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving BellRing Brands, Inc. and its officers or directors [1] Financial Performance - On May 6, 2025, BellRing announced that customers were optimizing inventories, leading to a slowdown in sales growth to "low-single-digits" for Q3 2025, resulting in a stock price drop of $14.88 per share, or 18.97%, closing at $63.55 [3] - On August 4, 2025, BellRing reported a 71.4% decline in unadjusted net earnings to $0.16 per share and narrowed its 2025 net sales outlook to $2.28 billion to $2.32 billion, down from $2.26 billion to $2.34 billion, causing a stock price drop of $17.46 per share, or 32.55%, closing at $36.18 [4]